Skyhawk Therapeutics annonce les résultats finaux à quinze mois de l'essai clinique de phase 1/2 du SKY-0515 chez des patients atteints de la maladie de Huntington

Skyhawk’s oral Huntington’s candidate SKY-0515 delivered a statistically significant 1.59-point cUHDRS advantage over an external natural-history control at 15 months (p<0.001), with treated patients improving 0.94 points versus a 0.65-point decline in controls. At the 9 mg dose, the drug reduced mutant huntingtin protein by more than 60% and PMS1 mRNA by more than 25%, with no treatment-related serious adverse events reported. The encouraging but small final phase 1/2 dataset (n=15 at month 15) supports the ongoing placebo-controlled global phase 2/3 FALCON-HD program, which includes more than 200 patients across the combined development program.

Analysis

There is no direct public-equity expression: Skyhawk is private, so the headline is principally a read-through for Huntington’s disease risk appetite rather than an investable company-specific catalyst. The apparent efficacy signal should not be capitalized at face value, however: the long-duration comparison relies on an external natural-history cohort, only 15 treated patients contribute at the terminal assessment, and treatment exposure is no longer placebo-controlled after the initial period. Attrition, cross-study assessment differences, and exclusion of intercurrent events can each inflate a functional-disease-modification estimate even when biomarker engagement is real.

The more investable second-order implication is for gene-therapy programs, especially uniQure (QURE) and its AMT-130 Huntington franchise. A credible oral approach that produces durable functional benefit would validate the commercial value of slowing disease progression, but it also raises the efficacy bar for irreversible, procedure-intensive intracranial gene therapy: convenience, scalability, and likely lower total cost could compress QURE’s eventual addressable market if SKY-0515 reproduces its signal in a contemporaneous placebo-controlled study. Near term, the data are modestly supportive for QURE by reducing category skepticism; over 6-18 months, confirmed oral efficacy would be competitively negative unless AMT-130 demonstrates clearly superior durability or magnitude.

Consensus enthusiasm is likely underpricing trial-design risk rather than underpricing the biology. Biomarker reduction alone does not establish that the observed clinical separation is causal, durable, or reproducible across a broader stage-2/3 population. The decisive catalyst is a blinded placebo-controlled FALCON efficacy dataset, not further company characterization of this completed small study; absent disclosed timing, this is a watch item rather than a calendar-driven trade.

Key Decisions for Investors

• No standalone position in response to this release: Skyhawk is private and the clinical evidence is insufficiently controlled to justify a sector-beta trade.
• Maintain QURE as a monitored read-through, not a new long. Reassess AMT-130 valuation if a controlled SKY-0515 dataset confirms functional benefit; an oral competitor could reduce QURE’s terminal penetration and pricing assumptions despite validating Huntington’s disease as a treatable market.
• For existing QURE longs, consider protective downside hedges into the next material Huntington data event rather than adding on category optimism; the key falsifier of the competitive-risk thesis is a clinically material and durable AMT-130 advantage versus an oral alternative.
• Set an alert for FALCON design and timing disclosures, particularly placebo duration, primary endpoint, multiplicity control, missing-data handling, and dose-response. A robust pre-specified placebo-controlled effect with materially larger patient exposure would warrant revisiting private-market exposure to RNA-splicing platforms and reducing long-term QURE terminal-value assumptions.